Main elements for me in this update :
- clear revenue acceleration (+ 11 % at the end of April vs + 6 % during H1 24) due both to an improvement of revenue retention (98 % vs 95 % during H1) and more new businesses (8.4 m$ so far in H2 vs 4.5 m$ in H1),
- margin still boosted by cost contained.
The most surprising element may be that most of the new business comes from Collaborate which was showing clear signs of decline. So we probably need some explanations from the company about this.
Based on their FY 24 guidance, the company has an EV/EBITDA of 3.7 x (share price : 0.57 $).
- Forums
- ASX - By Stock
- IRI
- Ann: FY24 Trading Update
Ann: FY24 Trading Update, page-6
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IRI (ASX) to my watchlist
(20min delay)
|
|||||
Last
92.0¢ |
Change
0.040(4.55%) |
Mkt cap ! $160.6M |
Open | High | Low | Value | Volume |
89.5¢ | 92.3¢ | 87.0¢ | $202.1K | 225.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5039 | 91.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
92.0¢ | 7479 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5039 | 0.910 |
1 | 1000 | 0.900 |
1 | 1000 | 0.895 |
1 | 37731 | 0.890 |
1 | 600 | 0.880 |
Price($) | Vol. | No. |
---|---|---|
0.920 | 7479 | 1 |
0.925 | 750 | 1 |
0.950 | 97311 | 4 |
0.960 | 10000 | 1 |
0.970 | 23310 | 3 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
IRI (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online